Last reviewed · How we verify
NCT05362578
Transcutaneous Electrical Acustimulation (TEA) for Gastroparesis
NA trial testing transcutaneous electrical accustimulation at treatment point. in Gastroparesis With Diabetes Mellitus in 41 participants. Completed in 28 February 2025.
28 February 2025
Quick facts
| Lead sponsor | University of Michigan |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 41 |
| Start date | 8 September 2022 |
| Primary completion | 28 February 2025 |
| Estimated completion | 28 February 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- transcutaneous electrical accustimulation at treatment point.
- transcutaneous electrical accustimulation at sham point.
Conditions studied
- Gastroparesis With Diabetes Mellitus — all drugs for Gastroparesis With Diabetes Mellitus →
Sponsor
University of Michigan
Who can join
Adults 18 to 80, any sex, with Gastroparesis With Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The device being studied, the Transcutaneous Electrical Accustimulator (TEA), will deliver weak electrical current at two specific points, one at the leg and the other at the arm at settings known to improve symptoms involving the digestive system. The study team would like to test if the device will impact the gastrointestinal (GI) symptoms and gastric motility in study participants with gastroparesis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05362578
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastroparesis With Diabetes Mellitus
Currently open trials in the same condition.
- NCT06661668 — Laparoscopic Implantation of a Gastric Pacemaker in the Treatment of Gastroparesis · recruiting
Other University of Michigan trials
Trials by the same sponsor.
- NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation · NA · not yet recruiting
- NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD) · NA · not yet recruiting
- NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness · NA · not yet recruiting
- NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health · NA · not yet recruiting
- NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05362578 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Michigan
- Last refreshed: 2 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05362578.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing